Cidara Therapeutics Inc
NASDAQ:CDTX
Balance Sheet
Balance Sheet Decomposition
Cidara Therapeutics Inc
Cidara Therapeutics Inc
Balance Sheet
Cidara Therapeutics Inc
| Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||
| Cash & Cash Equivalents |
0
|
23
|
63
|
85
|
61
|
75
|
50
|
36
|
60
|
33
|
36
|
190
|
|
| Cash Equivalents |
0
|
23
|
63
|
85
|
61
|
75
|
50
|
36
|
60
|
33
|
36
|
190
|
|
| Short-Term Investments |
0
|
0
|
45
|
19
|
15
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
6
|
11
|
5
|
6
|
16
|
2
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
6
|
11
|
5
|
6
|
16
|
2
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
6
|
0
|
|
| Other Current Assets |
0
|
0
|
1
|
1
|
2
|
3
|
10
|
10
|
7
|
7
|
3
|
19
|
|
| Total Current Assets |
0
|
23
|
108
|
105
|
78
|
77
|
66
|
57
|
72
|
45
|
61
|
211
|
|
| PP&E Net |
0
|
1
|
2
|
1
|
1
|
1
|
2
|
1
|
3
|
1
|
5
|
4
|
|
| PP&E Gross |
0
|
0
|
2
|
1
|
1
|
1
|
2
|
1
|
3
|
1
|
5
|
4
|
|
| Accumulated Depreciation |
0
|
0
|
1
|
1
|
2
|
3
|
3
|
3
|
3
|
3
|
3
|
3
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
1
|
1
|
1
|
0
|
|
| Total Assets |
0
N/A
|
24
+12 014%
|
110
+352%
|
107
-3%
|
79
-26%
|
79
+0%
|
69
-13%
|
60
-12%
|
75
+25%
|
47
-37%
|
67
+41%
|
215
+220%
|
|
| Liabilities | |||||||||||||
| Accounts Payable |
0
|
1
|
3
|
3
|
3
|
3
|
2
|
5
|
1
|
1
|
4
|
4
|
|
| Accrued Liabilities |
0
|
2
|
3
|
6
|
7
|
7
|
9
|
13
|
16
|
25
|
38
|
46
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
3
|
10
|
10
|
7
|
3
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
10
|
14
|
14
|
15
|
25
|
0
|
|
| Total Current Liabilities |
0
|
3
|
6
|
9
|
12
|
20
|
30
|
39
|
34
|
41
|
67
|
50
|
|
| Long-Term Debt |
1
|
0
|
0
|
10
|
7
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
11
|
20
|
21
|
7
|
2
|
|
| Total Liabilities |
2
N/A
|
3
+103%
|
6
+87%
|
19
+210%
|
19
+3%
|
20
+4%
|
31
+56%
|
50
+60%
|
54
+8%
|
62
+15%
|
75
+22%
|
51
-32%
|
|
| Equity | |||||||||||||
| Common Stock |
0
|
33
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
1
|
13
|
45
|
94
|
149
|
219
|
260
|
335
|
377
|
419
|
441
|
611
|
|
| Additional Paid In Capital |
0
|
2
|
149
|
182
|
209
|
278
|
298
|
345
|
399
|
404
|
433
|
775
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
1
N/A
|
21
N/A
|
104
+392%
|
88
-15%
|
60
-32%
|
59
-1%
|
38
-36%
|
11
-72%
|
22
+101%
|
14
N/A
|
8
+43%
|
163
N/A
|
|
| Total Liabilities & Equity |
0
N/A
|
24
+12 014%
|
110
+352%
|
107
-3%
|
79
-26%
|
79
+0%
|
69
-13%
|
60
-12%
|
75
+25%
|
47
-37%
|
67
+41%
|
215
+220%
|
|
| Shares Outstanding | |||||||||||||
| Common Shares Outstanding |
1
|
1
|
1
|
1
|
1
|
1
|
2
|
2
|
3
|
4
|
5
|
11
|
|